Phase 1 Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors Sponsored by ModeX Therapeutics, An OPKO Health Company
About this study This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Enrolling at this location MD Anderson Cancer Center
Houston, Texas
I'm interested This study also enrolls at 5 other locations. See all .
Study details Conditions
Biliary Tract Cancer Breast Cancer Cervical Cancer Colon Cancer Endometrial Cancer Esophageal Cancer Gastric Cancer GastroEsophageal Cancer Head and Neck Cancer Hepatocellular Cancer Non-small Cell Lung Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Renal Cancer Thyroid Cancer
Gender
All genders welcome
Healthy volunteers
Not accepted
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov .
Clinably Connecting patients with clinical research opportunities near them.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you meet the criteria to participate. Results are based on the information you provide and are intended to help you start a conversation with the research team.
© 2026 Clinably. Trial data sourced from ClinicalTrials.gov.